MetasTx is working to block metastases of cancer cells from solid tumors including prostate, breast and skin by early detection and blockade of mesenchymal-to-epithelial transition (EMT). Creating novel drug focused on inhibiting P21-activated kinase (PAK 1) and companion diagnostic to detect activation of EMT. Initial target - 2 million men on active surveillance for prostate cancer. Market Opportunity $11.5 billion US drug market, Mortality rates unchanged over the past 2 decades despite 35 drugs available. Platform focus – Inhibit EMT Target PAK1 to create First-In-Class drug to inhibit metastases. Personalized and aggressive treatment intervention when needed. Avoid unnecessary prostatectomies. MetasTx Strengths: 1. Science Foundation – 35 published articles 2. Demonstrated capabilities for AI Drug and Biomarker Discovery 3. Efficient business strategy / Laser focus on exit by Acquisition 4. Extraordinary Leadership Team Seeking lead for preferred equity Round of $2.5 M.